REPLY
18.6.2024 10:01:34 CEST | Business Wire | Press release
Reply, an international group specialised in creating new business models enabled by AI and Digital Media, introduces the jury that will be tasked with evaluating and selecting the best short films for the Reply AI Film Festival, an international competition open to all creatives eager to engage in creating a short film using AI tools.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618976841/en/
Reply presents the inaugural Reply AI Film Festival, an international competition where Artificial Intelligence (AI) serves not only as a catalyst for innovation in the realm of creative storytelling but also as a tool for fostering inclusivity among younger generations in video and film production. (Photo: Reply)
Judging the works submitted in the four competition categories - Narratives, Pilots, Documentaries, and Experimental - will be: Adam Kulick, producer of successful films such as Twilight, Wuthering Heights, and The Iron Lady, as well as a Sloan Fellow at Stanford University specialising in Generative AI; Caleb & Shelby Ward, co-founders of Curious Refuge, the first online community dedicated to directors using AI in their creations; Denise Negri, a journalist from SkyTg24 and Sky Arte, known for covering prestigious film events like the Academy Awards, Cannes Film Festival, and Venice Film Festival. Also participating are Filippo Rizzante, Chief Technology Officer at Reply; Flavio Natalia, director of Ciak and ciakmagazine.it, and an author and journalist for Ansa, Rai, and Sky; as well as the Canadian duo Vallée Duhamel, comprised of Julien Vallée and Eve Duhamel, who create unique short films for international brands using captivating images and videos that blend playful approaches with experimentation in new technologies such as artificial intelligence. Monica Riccioni, Chief Executive Officer of Think Cattleya, an advertising agency that has collaborated with numerous international directors and created campaigns for renowned global brands; Paul Trillo, a director and video artist known for his conceptual and visually inventive films, integrating new tools like AI with traditional techniques; and Rob Minkoff, co-director of The Lion King (1994) and animator and director of numerous films including Stuart Little, The Haunted Mansion, and Mr. Peabody & Sherman.
The jury will select the short films submitted to the competition via the platform aiff.reply.com by July 1, 2024, interpreting the theme of this first edition of the festival: Synthetic Stories, Human Hearts, a title that celebrates the convergence of human talent and artificial intelligence. In doing so, they will follow three main criteria: creativity, which refers to the innovative scope of cinematic language; craftsmanship, meaning the overall quality and value of the short film's production; and the impact of artificial intelligence, assessing how AI tools have contributed to one or more aspects of its creation.
Adam Kulick commented, "GenAI's integration into filmmaking processes opens up a new era of creativity and justifiable concerns. I'm hopeful that the fusion of human ingenuity and these rapidly evolving technologies produces groundbreaking work and new opportunities for the filmmaking community."
"We believe AI is going to act as a creative assistant in every part of the filmmaking pipeline. It’s going to allow for new stories to be told, it’s going to democratise the filmmaking industry and support filmmakers all around the world in telling their stories." said Caleb & Shelby Ward.
"AI is an increasingly valuable ally of creativity. We are truly delighted that such high-calibre figures in the film world have joined our initiative: a space to test AI as an ally of human creativity, but also an opportunity for young talents to immerse themselves in new technologies, acquire advanced skills, and bring new narratives to life," said Filippo Rizzante.
"I have always supported the potential of AI and believe that the combination of human and technological talent is not only possible but also enriches our work. This added value is something we at Think Cattleya greatly value and I am certain I will witness it during the screening of the short films in this competition," said Monica Riccioni.
"Specifically, AI's role should always be to assist the creatives, producers and crew working in film and not to replace them. It should not be used as a crutch or a shortcut for the creatively bankrupt. This is an opportunity for independent filmmakers to think out of the box and for smaller productions to create better, bolder and stranger films." confirmed Paul Trillo.
The ten best short films will be presented at a special premiere event organised by Reply, together with Mastercard, which has always been close to the world of cinema, connecting fans, performers and advocates to their passion. The event will take place during the days of the 81st Venice International Film Festival where the three overall winners will be announced.
To learn more about the Reply AI Film Festival, visit aiff.reply.com.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618976841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
